– First collaboration program, leveraging Cyrus’ de novo computational approach to create proprietary IL-2 protein agonist targeting autoimmune and other deleterious immune conditions- -Preclinical data demonstrate synergistic activity of ImmTOR in combination with IL-2 mutein to increase the level and durability of Treg expansion- – Unlocking a new generation of innovative biologic therapeutics with the potential […]

Summary Cyrus has developed a “NextGen” antibody structure prediction tool (NextGen) based on the RosettaCM “hybridize” algorithm (1). Cyrus customized and modified RosettaCM for antibody structures with an antibody-specific database, sequence parsing, and by taking antibody-specific heavy-light chain orientation into account.  NextGen was developed and benchmarked on the test set of antibody structures from the […]